Palantir or AMD: Raymond James Chooses the Better AI Stock to Buy After Earnings
January finished with an earthquake in the tech world, when the Chinese startup DeepSeek released its new AI assistant – and revealed that it
Raymond James cuts e.l.f. Beauty stock target to $120
James maintained a Strong Buy rating on e.l.f. Beauty (NYSE:ELF) shares but reduced the price target from $175.00 to $120.00. The firm's analyst cited the company's third-quarter sales, which surpassed expectations with a 31% year-over-year increase compared to the projected 22%.
Raymond James Financial Inc. stock outperforms competitors on strong trading day
This was the stock's second consecutive day of gains.
Regenxbio resumed with an Outperform at Raymond James
Raymond James resumed coverage of Regenxbio (RGNX) with an Outperform rating and $27 price target The firm expects the launch of Elevidys and
Raymond James lifts Tradeweb stock target to $144, maintains Outperform
James updated its outlook on Tradeweb Markets (NASDAQ:TW), with analyst Patrick O'Shaughnessy increasing the price target to $144 from $141 while sustaining an Outperform rating on the company's stock.
Symbotic falls as Raymond James downgrades stock on disappointing earnings
Symbotic (NASDAQ:SYM) shares fell more than 17% in Thursday trade after Raymond James downgraded its rating from Outperform to Market Perform following a disappointing first quarter results. The Massachusetts-based warehouse automation company reported both top-line and bottom-line misses on Wednesday,
Allied Properties price target lowered to C$18 from C$19 at Raymond James
Raymond James lowered the firm’s price target on Allied Properties (APYRF) to C$18 from C$19 and keeps a Market Perform rating on the
Big Tech's underperformance is just a blip, says Raymond James' Larry Adam
Larry Adam, Raymond James chief investment officer, joins 'The Exchange' to discuss key takeaways from Big Tech earnings, ...
Business Insider16h
Haemonetics price target lowered to $115 from $120 at Raymond James
Raymond James lowered the firm’s price target on Haemonetics (HAE) to $115 from $120 and keeps a Strong Buy rating on the shares. Shares sold off sharply following the Q3 results, but Raymond ...
Raymond James: Strong Balance Sheet And Cash Economics Are In The Price
Raymond James is seeing a beneficial shift to advisory as well as recovering M&A activity, which may continue. Read why I ...
InvestmentNews1d
LPL, Raymond James boost advisor ranks anew
LPL Financial welcomes a $345 million investment and planning team from Ameriprise as RayJay's employee advisor arm adds a ...
Robinhood Markets (NASDAQ:HOOD) Now Covered by Raymond James
Investment analysts at Raymond James assumed coverage on shares of Robinhood Markets (NASDAQ:HOOD – Get Free Report) in a ...
Raymond James Becomes Latest Financial Firm to Dial Back on Reporting Advisor Head Count
Following similar moves by other large firms, Raymond James says quarterly advisor counts aren’t the most meaningful measure ...
Financial Planning9d
Dynasty brings over $6.4B RIA from Raymond James
Jeffrey Dobyns, the president of SageSpring Wealth Partners, says he and his colleagues were looking for greater freedom to ...
Seaport Res Ptn Lifts Earnings Estimates for Raymond James
Stock analysts at Seaport Res Ptn raised their Q3 2025 earnings per share estimates for Raymond James in a report released on ...
WealthManagement.com7d
Raymond James Sees Recruiting Cool; Ameriprise Adds 91 Advisors
In earnings calls, both Raymond James and Ameriprise cited strong recruiting pipelines as they beat analysts’ income ...
Raymond James Sticks to Their Buy Rating for XPO (XPO)
In a report released today, Patrick Brown from Raymond James maintained a Buy rating on XPO (XPO – Research Report), with a price target of ...